Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

In this study, we aimed to evaluate axillary lymph node dissection (ALND) rates and prognosis in neoadjuvant chemotherapy (NCT) compare with neoadjuvant endocrine therapy (NET) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), lymph node (LN)-positive, pr...

Full description

Bibliographic Details
Main Authors: Sungchan Gwark, Woo Chul Noh, Sei Hyun Ahn, Eun Sook Lee, Yongsik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyungyub Gong, Seon-Ok Kim, Hee Jeong Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
axillary lymph node dissection
survival
prognosis
neoadjuvant chemotherapy
neoadjuvant endocrine therapy
neoadjuvant study of chemotherapy versus Endocrine therapy in premenopausal patient with hormone responsive
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.741120/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.741120/full

Similar Items